existing oral semaglutide approvals, including Novo's Rybelsus and Torrent's generics, remain cleared only for type 2 diabetes management
Combining them is meant to recruit the amylin pathway on top of the GLP-1 pathway, and the two were formally co-administered and tested together as CagriSema. [4] For the amylin side of that equation, our references on how cagrilintide affects gastric emptying and post-prandial metabolism and how cagrilintide influences brain satiety circuits go deeper into the mechanism
Semaglutide and Tirzepatide work by slowing gastric emptying, increasing feelings of fullness, and reducing hunger
doi: 10.1016/j.jdiacomp.2022.108362
Treating it requires more than a one-size-fits-all approach
It is being studied for its potential to improve glycemic control and assist in weight management in individuals with and without T2D, at a maximum dose of 12mg/weekly [11]